Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.
Resignations
On April 18, 2017, Bryan Lee, PhD resigned as President and Chief Executive Officer, and Director of the Companys Board, effective immediately. Mr. Lees resignation does not arise from any disagreement on any matter relating to the Companys operations, policies or practices, or regarding the general direction of the Company.
On April 18, 2017, Mr. Stefan Moll resigned as Chief Financial Officer, effective immediately. Mr. Molls resignation does not arise from any disagreement on any matter relating to the Companys operations, policies or practices, or regarding the general direction of the Company.
On April 18, 2017, Mr. Oliver Jackson resigned as Director of the Companys Board, effective immediately. Mr. Jacksons resignation does not arise from any disagreement on any matter relating to the Companys operations, policies or practices, or regarding the general direction of the Company.
Appointments
On April 18, 2017, the Board of Directors of the Company appointed Ms. Sophia Yaqi Sun as President & Chief Executive Officer, and Director of the Companys Board, effective immediately.
Ms. Sun (age 35) is the Senior Vice President of Medisun Holdings Limited (Medisun, together with its subsidiaries and its affiliated companies, collectively, the Medisun Group), and the Vice President of National Investments Fund Limited (NIF). The Medisun Group is a group of companies principally engaged in medical and healthcare related businesses, and is committed to stem cell regenerative and precision medicine industry investments and the commercialization of regenerative and precision medicine technologies. NIF is a company incorporated in the Cayman Islands, the shares of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited. Prior to joining Medisun and NIF, Ms. Sun has worked for Ernst & Young LLP in Beijing and San Francisco, leading audit teams in financial auditing, bad debt evaluation, merger acquisition due diligence for commercial banks. Ms. Sun attained her Bachelors degree at University of International Business and Economics in the Peoples Republic of China, and her Master of Business Administration degree at the University of Illinois.
On April 18, 2017, the Board of Directors of the Company appointed Ms. Lisha Huang as Director of the Companys Board, effective immediately.
Ms. Huang (age 57) has been a Director of Medisun Holdings Limited and Medisun Group companies since 2014. Prior, Ms. Huang was an Executive Director of New Sakai Hong Kong Limited, a company incorporated in Hong Kong.